miRNAs Biomarkers for Pancreatic Cancer

MicroRNA (miRNAs) have been shown to play important roles in oncogenesis and tumor metastasis of various carcinomas including pancreatic cancer. Recently, an increasing number of studies have reported the potential value of miRNAs as biomarkers for PC diagnosis. Based on the advanced platforms and experienced experts, Alfa Cytology fully assists our customers in exploring, discovering, and validating miRNAs, which are considered to be the most widespread and promising non-invasive biomarkers in pancreatic cancer.

Overview of miRNAs Biomarkers in Pancreatic Cancer

miRNAs are small, non-coding RNA molecules, typically 18-25 nucleotides in length, that regulate gene expression post-transcriptionally by binding to the 3'-untranslated regions (UTRs) of target mRNA. Their ability to regulate hundreds of mRNAs makes them pivotal in various cellular processes, including cancer development. A large number of miRNAs are shown to be dysregulated during and after PC development. miRNAs are considered to be one of the most popular non-invasive biomarkers in PC diagnosis. However, before clinical application to patients, validation studies in a larger cohort and consensus on the final identification panel are needed. Notably, miRNAs can be stably detected in plasma and serum due to their protection from RNase activity within micro-vesicular bodies like exosomes, as well as through their association with lipoprotein and protein complexes such as Ago2.

Fig. 1 miRNA as Biomarker in Cancer (Lobera ES, et al., 2023)

Our Services

Alfa Cytology is an integrated research, development, and manufacturing organization providing scientific services, primarily ranging from early discovery and development to preclinical research. We have a wide range of techniques for miRNA evaluation, such as next-generation sequencing (NGS), miRNA microarray, in situ hybridization, droplet digital PCR (ddPCR), and reverse transcription-quantitative PCR (RT-qPCR), which can detect and identify miRNAs in various body fluids.

•  Development of blood miRNAs as biomarkers for pancreatic cancer diagnosis • Development of fecal miRNAs as biomarkers for pancreatic cancer diagnosis • Development of urinary miRNAs as biomarkers for pancreatic cancer diagnosis • Development of salivary miRNAs as biomarkers for pancreatic cancer diagnosis

In addition to the above services, we also support:

• Development of miRNA panels for pancreatic cancer diagnosis
• Combination of miRNAs and other types of biomarkers in a panel for pancreatic cancer diagnosis
• Validation studies in a larger cohort

Why Choose Us?

Scientific Experience

Professional team of scientists and more than ten years of experience in pancreatic cancer

Customized Service

Tailored services dedicated to ensuring customer satisfaction

Data Security

Strictly keep confidential the client's project information and experimental data

Quick Reply

Our customer service representatives are available 24 hours a day from Monday to Sunday

If you are interested in learning more about our PC diagnostic development services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please don't hesitate to contact us. Our professional and patient staff will contact you as soon as possible.

References

1. Herreros-Villanueva, Marta, and Luis Bujanda. "Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have." Annals of translational medicine 4.7 (2016).
2. Yang, Jinshou, et al. "Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review." Cancer Communications 41.12 (2021): 1257-1274.
3. Lobera ES, Varela MA, Jimenez RL, Moreno RB. miRNA as biomarker in lung cancer. Mol Biol Rep. 2023 Nov;50(11):9521-9527.